文献速递类风湿关节炎

新促炎细胞因子IL-40由活化中性粒细胞产生并在血清阳性类风湿关节炎早期阶段发挥作用

New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis.
PubMed 文献 · RMD Open · 2023-01-01

研究检测了未治疗早期类风湿关节炎(ERA)患者基线及传统治疗3个月后的血清IL-40,并与健康对照比较。结果显示ERA患者血清IL-40升高且治疗后恢复正常,与自身抗体及NETosis标志物相关,中性粒细胞是IL-40的重要来源,IL-40可能参与ERA。

要点

  • ERA患者基线血清IL-40较健康对照升高(p<0.0001),传统治疗3个月后恢复正常(p<0.0001)。
  • 基线IL-40与类风湿因子(IgM)、抗环瓜氨酸肽抗体及NETosis标志物相关。
  • 中性粒细胞在NETosis诱导或细胞因子刺激下增强IL-40分泌,重组IL-40可上调IL-1β、IL-6和IL-8。

核心结论

  • IL-40在血清阳性ERA中显著上调,传统治疗后下降。
  • 中性粒细胞是RA中IL-40的重要来源,其释放由细胞因子和NETosis增强。
  • IL-40可能在ERA中发挥作用。

研究设计与样本

  • 研究检测未治疗ERA患者基线(n=60)及传统治疗3个月后的血清IL-40,并与健康对照(n=60)比较。
  • 采用ELISA检测IL-40、细胞因子和NETosis标志物,免疫荧光观察NETosis,并对14例ERA患者外周血中性粒细胞进行体外实验。

主要发现

  • ERA患者血清IL-40较健康对照升高(p<0.0001),治疗3个月后恢复正常(p<0.0001)。
  • 基线血清IL-40与类风湿因子(IgM)(p<0.01)、抗环瓜氨酸肽抗体(p<0.01)及NETosis标志物(蛋白酶3、中性粒细胞弹性蛋白酶(NE)、髓过氧化物酶)(p<0.0001)相关。
  • 治疗后NE水平显著下降(p<0.01),且与血清IL-40下降相关(p<0.05)。
  • 体外实验中,中性粒细胞在NETosis诱导后(p<0.001)或暴露于IL-1β、IL-8(p<0.05)、肿瘤坏死因子或脂多糖(p<0.01)后IL-40分泌增强。
  • 重组IL-40在体外上调IL-1β、IL-6和IL-8(p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interleukin (IL)-40 is a new cytokine related to immune system function and malignancies. Recently, an association of IL-40 with rheumatoid arthritis (RA) and externalisation of neutrophil extracellular traps (NETosis) was found. As neutrophils are implicated in RA development, we investigated IL-40 in early stages of RA (ERA). METHODS: IL-40 was determined in serum of treatment naïve patients with ERA at baseline (n=60) and 3 months after initiation of conventional therapy and in healthy controls (HC; n=60). Levels of IL-40, cytokines and NETosis markers were measured by ELISA. NETosis was visualised by immunofluorescence. In vitro experiments were performed on peripheral blood neutrophils from ERA patients (n=14). Cell-free DNA was analysed in serum and supernatants. RESULTS: Serum IL-40 was elevated in ERA compared with HC (p<0.0001) and normalised after 3 months of therapy (p<0.0001). Baseline serum IL-40 correlated with rheumatoid factor (IgM) (p<0.01), anti-cyclic citrullinated peptide (p<0.01) autoantibodies and NETosis markers (proteinase 3; neutrophil elastase (NE); myeloperoxidase) (p<0.0001). Levels of NE significantly decreased after therapy (p<0.01) and correlated with the decrease of serum IL-40 (p<0.05). In vitro, neutrophils enhanced IL-40 secretion following NETosis induction (p<0.001) or after exposure to IL-1β, IL-8 (p<0.05), tumour necrosis factor or lipopolysaccharide (p<0.01). Recombinant IL-40 up-regulated IL-1β, IL-6 and IL-8 (p<0.05 for all) in vitro. CONCLUSION: We showed that IL-40 is significantly up-regulated in seropositive ERA and decreases after conventional therapy. Moreover, neutrophils are an important source of IL-40 in RA, and its release is potentiated by cytokines and NETosis. Thus, IL-40 may play a role in ERA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Navrátilová A, Bečvář V, Hulejová H, et al. New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis. RMD Open. 2023. PMID: 37208028. doi:10.1136/rmdopen-2022-002894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。